Recurrent Melanoma Completed Phase 1 Trials for Decitabine (DB01262)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00030615Decitabine in Treating Patients With Advanced Solid TumorsTreatment